Introduction: The RBD included 44 mutation sites, in which the S77N, V483A, A344S, and N501Y mutations were the most frequent, while the Y453, G476, F486, T500, and N501 mutations were close to the ACE2 (Guruprasad).
A comprehensive overview of identified mutations in SARS CoV-2 spike glycoprotein among Iranian patients.
Introduction: While most of alterations in the receptor binding domain (RBD) reduce infectivity, A475V, L452R, V483A, and F490L variants induce resistance to some neutralizing antibodies.
Computational investigation reveals that the mutant strains of SARS-CoV2 have differential structural and binding properties.
PMID: 34968787
2022
Computer methods and programs in biomedicine
Abstract: Furthermore, the binding strength of different MTs along with WT (wildtype) was revealed that MTs showed differential binding affinities to host protein with high binding strength exhibited by V367F and V483A MTs.
Introduction: In addition, mutations such as G476S (Glycine 476 to Serine) and V483A (Valine 483 to Alanine) were reported in the United States.
Introduction: Moreover, RBD MTs such as V367F and V483A showed high binding affinities to the host ACE2 receptor protein.
Introduction: Of these five, three mutations such as G476S, V483A and N501Y
SARS-CoV-2 phase I transmission and mutability linked to the interplay of climatic variables: a global observation on the pandemic spread.
PMID: 35028838
2022
Environmental science and pollution research international
Introduction: Apart from this, L5F was also observed in 37 countries; Q239K, V483A, and D839Y/N/E in Europe; G476S and V483A in the USA; and P1263L in the UK.
Characterization of a Broadly Neutralizing Monoclonal Antibody against SARS-CoV-2 Variants.
Result: Of the 5,343,811 available sequences, the mutation V483F appeared in 2699 sequences (0.0005%), and V483A appeared in 328 sequences, while 99.93% of the sequences were invariant.
Evolutionary shift from purifying selection towards divergent selection of SARS-CoV2 favors its invasion into multiple human organs.
Result: But the present data of SARS-CoV2 mutation profile does not support that this region is refractory to nucleotide changes to generate nonsynonymous mutation as and identified numerous nonsynonymous mutations (C480F, Y495S, L517F and G476S, V483A,Y508H respectively) in this region in SARS-CoV2.
V483A: an emerging mutation hotspot of SARS-CoV-2.
Abstract: V483A mutant virus is popular in North America with 36 cases so far and frequently occurring in recent days.
Abstract: One of the many mutations that have occurred in the viral genome is the V483A mutation, which is a part of the receptor-binding motif present in the S1 domain of the spike protein.
Abstract: This review compares the wild-type and the V483A mutants to analyze certain factors like the interaction between the virus and host-cell interface, binding affinity, stability, partition energy, hydrophobicity, occurrence rate and transmissibility.
Introduction: Apart from the primary (amino acid change) and secondary (loop structure) changes observed at the RBM of S protein due to V483A mutation, there are few gains in functions like higher solvent acce
Anti-SARS-CoV-2 Vaccines and Monoclonal Antibodies Facing Viral Variants.
Introduction: It is characterized by nine mutations, and one deletion in the Spike, in particular H655Y, the 144 deletion (in common with 20I/501Y.V1), D215G (in common with 20H/501Y.V2), and V483A, near to the E484K residue in 20J/501Y.V3.
Introduction: It is characterized by nine mutations, and one deletion in the Spike; in particular, these include H655Y, which is also present in the 20J/501Y.V3 and 19B/501Y variants; the Y144 deletion common with 20I/501Y.V1; the D215G mutation in common with the 20H/501Y.V2 variant; and the V483A close to the E484 residue mutated in the 20J/501Y.V3 variant (E484K), which may be involved in post-vaccine or
Revealing the Threat of Emerging SARS-CoV-2 Mutations to Antibody Therapies.
Abstract: We unveil, for the first time, that high-frequency mutations R346K/S, N439K, G446V, L455F, V483F/A, F486L, F490L/S, Q493L, and S494P might compromise some of mAbs in clinical trials.
Ongoing global and regional adaptive evolution of SARS-CoV-2.
SARS_CoV_2 mutation literature information.
PMID: 
2022
Journal of applied genetics
Browser Board
Co-occurred Entities
Filtrator
ViMRT